Lilly's Zepbound Receives FDA Approval for Sleep Apnea
Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. OSA is a common sleep-related breathing disorder that causes repeated interruptions in breathing (apnea) or shallow breathing (hypopnea) during sleep.